Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

663 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
Miyamoto S, Heerspink HJL, de Zeeuw D, Sakamoto K, Yoshida M, Toyoda M, Suzuki D, Hatanaka T, Nakamura T, Kamei S, Murao S, Hida K, Ando S, Akai H, Takahashi Y, Kitada M, Sugano H, Nunoue T, Nakamura A, Sasaki M, Nakatou T, Fujimoto K, Kawanami D, Wada T, Miyatake N, Kuramoto H, Shikata K; CANPIONE study Investigators. Miyamoto S, et al. Among authors: de zeeuw d. Kidney Int. 2024 Nov;106(5):972-984. doi: 10.1016/j.kint.2024.08.019. Epub 2024 Aug 30. Kidney Int. 2024. PMID: 39216659 Free article. Clinical Trial.
Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical Trials.
Ku E, Inker LA, Tighiouart H, McCulloch CE, Adingwupu OM, Greene T, Estacio RO, Woodward M, de Zeeuw D, Lewis JB, Hannedouche T, Jafar TH, Imai E, Remuzzi G, Heerspink HJL, Hou FF, Toto RD, Li PK, Sarnak MJ. Ku E, et al. Among authors: de zeeuw d. Ann Intern Med. 2024 Jul;177(7):953-963. doi: 10.7326/M23-3236. Epub 2024 Jul 2. Ann Intern Med. 2024. PMID: 38950402
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
Cardoza K, Kang A, Smyth B, Yi TW, Pollock C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Wheeler DC, Zhang H, Cannon CP, Perkovic V, Arnott C, Levin A, Mahaffey KW. Cardoza K, et al. Among authors: de zeeuw d. Diabetes Obes Metab. 2024 Sep;26(9):3530-3540. doi: 10.1111/dom.15685. Epub 2024 Jun 19. Diabetes Obes Metab. 2024. PMID: 38895796 Clinical Trial.
Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes.
Ku E, Tighiouart H, McCulloch CE, Inker LA, Adingwupu OM, Greene T, Estacio RO, Woodward M, de Zeeuw D, Lewis JB, Hannedouche T, Hou FF, Jafar TH, Imai E, Remuzzi G, Heerspink HJL, Toto RD, Sarnak MJ. Ku E, et al. Among authors: de zeeuw d. J Am Soc Nephrol. 2024 Oct 1;35(10):1402-1411. doi: 10.1681/ASN.0000000000000426. Epub 2024 Jun 18. J Am Soc Nephrol. 2024. PMID: 38889197
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
Bornstein SR, de Zeeuw D, Heerspink HJL, Schulze F, Cronin L, Wenz A, Tuttle KR, Hadjadj S, Rossing P. Bornstein SR, et al. Among authors: de zeeuw d. Diabetes Obes Metab. 2024 Jun;26(6):2128-2138. doi: 10.1111/dom.15518. Epub 2024 Mar 18. Diabetes Obes Metab. 2024. PMID: 38497241 Clinical Trial.
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.
Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P; ASi in CKD group. Tuttle KR, et al. Among authors: de zeeuw d. Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15. Lancet. 2024. PMID: 38109916 Clinical Trial.
663 results